Ziyuglycoside II suppressed the progression of osteosarcoma by coordinating estrogen-related receptor gamma and p53 signaling pathway
- 22 March 2025
- journal article
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (3) , 354-367
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China
- National Natural Science Foundation of China
This publication has 38 references indexed in Scilit:
- Curcumin in human osteosarcoma: From analogs to carriersDrug Discovery Today, 2022
- The p53 network: cellular and systemic DNA damage responses in cancer and agingTrends in Genetics, 2022
- Potential of natural products in osteosarcoma treatment: Focus on molecular mechanismsBiomedicine & Pharmacotherapy, 2021
- Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- Osteocytes and CancerCurrent Osteoporosis Reports, 2021
- p53 and Tumor Suppression: It Takes a NetworkTrends in Cell Biology, 2021
- Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiationBiomedicine & Pharmacotherapy, 2020
- Antiangiogenic Effects of Ziyuglycoside II, a Major Active Compound of Sanguisorba officinalis L.Phytotherapy Research, 2017
- Divergent regulation of theOsteopontinpromoter by the estrogen receptor-related receptors is isoform- and cell context dependentJournal of Cellular Biochemistry, 2013
- miR-378 ∗ Mediates Metabolic Shift in Breast Cancer Cells via the PGC-1β/ERRγ Transcriptional PathwayCell Metabolism, 2010